Abstract:Heterozygous mutations in the granulin ( GRN ) gene may result in haploinsufficiency of progranulin (PGRN), which might lead to frontotemporal dementia (FTD). In this study, we aimed to perform analytical and clinical validation of a commercial progranulin kit for clinical use. Analytical validation parameters including assay precision, selectivity, measurement range, dilution linearity, interferences and sample stability were tested according to previously described procedures. For clinical validation, PGRN levels were measured in plasma from 32 cognitively healthy individuals, 52 confirmed GRN mutation carriers, 25 C9orf72 mutation carriers and 216 patients with different neurodegenerative diseases of which 70 were confirmed as non-mutation carriers. Among the analytical validation parameters, assay precision and repeatability were very stable (coefficients of variation <7 %). Spike recovery was 96 %, the measurement range was 6.25–400 μg/L and dilution linearity ranged from 1:50–1:200. Hemolysis did not interfere with progranulin levels, and these were resistant to freeze/thaw cycles and storage at different temperatures. For the clinical validation, the assay was capable of distinguishing GRN mutation carriers from controls and non- GRN mutation carriers with very good sensitivity and specificity at a cut-off of 57 μg/L (97 %, 100 %, respectively). In this study, we demonstrate robust analytical and diagnostic performance of this commercial progranulin kit for implementation in clinical laboratory practice. This easy-to-use test allows identification of potential GRN mutation carriers, which may guide further evaluation of the patient. This assay might also be used to evaluate the effect of novel PGRN-targeting drugs and therapies.

The detection of GRN mutation carriers by progranulin blood protein levels from finger‐stick collection

Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias

Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort

The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia

Losing protein in the brain: the case of progranulin

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors

GRN Missense Variants and Familial Alzheimer's Disease: Two Case Reports

Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred

Frontotemporal Dementia due to the Novel GRN Arg161GlyfsX36 Mutation

GRN deletion in familial frontotemporal dementia showing association with clinical variability in 3 familial cases

Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes

Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg

A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations

Progranulin Gene Mutations in Chinese Patients with Frontotemporal Dementia: A Case Report and Literature Review

Elevated levels of extracellular vesicles in progranulin-deficient mice and FTD-GRN Patients

Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia

Single-cell multimodal analysis in a case with reduced penetrance of Progranulin-Frontotemporal Dementia

Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin

Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia

Progranulin mutations as risk factors for Alzheimer disease